Clinical Trial Update: Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and immunogenicity of two V114 formulations in adults 50+ with completed results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• V114 (15-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-04-02